18 February 2016
Smith & Nephew (NYSE:SNN;LSE:SN), the global medical technology business, today announced that its first BST-CarGel® procedure was successfully performed by Dr. Sergi Sastre, MD, PhD at Hospital Clínic in Barcelona, Spain. Acquired by Smith & Nephew in January, BST-CarGel is a first-line cartilage repair product used along with microfracture and other bone marrow stimulation techniques for the initial treatment of most sizes of focal cartilage tears. To date, BST-CarGel has been used in more than 1,000 surgeries across Europe, Canada and Australia.
“I continue to be very pleased with my patient outcomes following the implantation of BST-CarGel,” says Dr. Sastre, who used the product to treat a young male with an isolated cartilage lesion of the knee. “Especially for my younger patients, I see BST-CarGel as an important step toward successfully treating cartilage lesions in an attempt to delay the need for prostheses or other more invasive procedures.”
According to a study by Prof. Matthias Steinwachs from the SportClinic Zurich / Hirslanden Clinic, traditional bone marrow stimulation techniques have only reproduced mechanically inferior fibrous cartilage tissue. However, enhancing microfracture with a chitosan-based biomaterial such as BST-CarGel resulted in a significant improvement in the repair tissue quality.i
“The level 1 clinical data supporting the use of this product is impressive, showing both a greater quantity and better quality of tissue fill in the lesion when compared to microfracture alone.ii” says Dr Steinwachs. “The versatility of BST-CarGel allows it to be used either arthroscopically or through a mini arthrotomy.”
“We’ve already received tremendous interest from current Smith & Nephew customers as well as others looking for a solution that complements their current bone marrow stimulation technique and is supported by strong clinical evidence,” explains Diogo Moreira-Rato, President Europe and Canada
About BST CarGel
BST-CarGel is a biopolymer-based solution that is mixed with a patient’s blood and implanted into the joint following a microfracture procedure. BST-CarGel can be delivered arthroscopically and can be used to treat damaged cartilage in synovial joints such as the knee, hip, ankle and shoulder. Once implanted, it acts as a scaffold, adhering to the cartilage surface to stabilize the blood clot while new cartilage is regenerated.
Microfracture is a surgical option for treating small areas of damaged articular cartilage. During the procedure, the cartilage area is prepared by removing loose or damaged tissue. A surgical tool is then used to create a series of small, microfracture holes to access the bone’s vascular layer. When blood cells from the vascular layer travel through these holes to the bone’s surface, they can stimulate new cartilage growth. Microfracture surgery is not recommended for patients with widespread cartilage damage such as arthritis.
Smith & Nephew, US
+1 (978) 749-1330
Smith & Nephew, London
+44 (0)20 7401 7646
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2015 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.
◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.